Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carilex MedicalROCO:7726 34 PS Ratio is 1.91 as of Jul. 25, 2026, which is 13% below its 10-year median of 2.19. GuruFocus rates ROCO:7726 with a GF Score™ of 34/100. The stock has 5 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Carilex Medical ranks better than 61.32% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Carilex Medical's share price is NT$31.95.
Carilex Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$16.69. Hence, Carilex Medical's PS Ratio for today is 1.91.
The historical rank and industry rank for Carilex Medical's PS Ratio or its related term are showing as below:
ROCO:7726'
s PS Ratio Range Over the Past 10 Years
Min: 1.36 Med: 2.19 Max: 2.67
Current: 1.91
During the past 6 years, Carilex Medical's highest PS Ratio was 2.67. The lowest was 1.36. And the median was 2.19.
ROCO:7726's PS Ratio is ranked better than 61.32% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.83
vs ROCO:7726: 1.91
Carilex Medical Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Carilex Medical was -3.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -5.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -8.70% per year.
During the past 6 years, Carilex Medical's highest 3-Year average Revenue per Share Growth Rate was 0.60% per year. The lowest was -14.30% per year. And the median was -5.20% per year.
Back to Basics: PS Ratio
Carilex Medical (ROCO:7726) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Carilex Medical PS Ratio Related Terms
Carilex Medical PS Ratio Historical Data
* Premium members only.
The historical data trend for Carilex Medical's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Carilex Medical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carilex Medical PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carilex Medical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Carilex Medical's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Carilex Medical's Share Price of today is NT$31.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Carilex Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$16.69.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Carilex Medical (ROCO:7726) has a PS Ratio of 1.91 as of Jul. 25, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Carilex Medical and its competitors. This is 13% below median its historical median of 2.19. Over the past decade, Carilex Medical's PS Ratio has ranged from 1.36 to 2.67. According to the industry distribution chart, Carilex Medical ranks #311 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 38.7%.
Is Carilex Medical's PS Ratio too high?
Carilex Medical's current PS Ratio of 1.91 is 13% below median its 10-year median of 2.19. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 2.67. The Medical Devices & Instruments industry median PS Ratio is 2.83. Carilex Medical's value of 1.91 is 32.5% below this industry median. Based on the distribution chart, Carilex Medical ranks #311 out of 804 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Carilex Medical has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Carilex Medical ranks #311 out of 804 companies for PS Ratio. This puts Carilex Medical in the upper half of its industry. The industry median PS Ratio is 2.83. Carilex Medical's value of 1.91 is 32.5% below this benchmark. Historically, Carilex Medical's own PS Ratio has ranged from 1.36 to 2.67 over the past decade. While the company's 10-year median is 2.19 vs. the industry median of 2.83, Carilex Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.83, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carilex Medical's current PS Ratio of 1.91 is 32.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Carilex Medical and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carilex Medical's current PS Ratio is 1.91, which is 13% below median its own 10-year median of 2.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current PS Ratio of 1.91. The current PS Ratio is 1.91, which is 13% below median its 10-year median of 2.19 and 32.5% below the Medical Devices & Instruments industry median of 2.83. Carilex Medical's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current PS Ratio is 1.91 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
34GF Score
Get the complete analysis for ROCO:7726
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7726 has been successfully added to your 
